.svg)
.svg)
.svg)
.svg){kind=icon}
.svg)
.svg){kind=icon}
.svg)
.svg){kind=icon}
.svg)
.svg){kind=icon}
.svg){kind=icon}
.svg){kind=icon}
Publication date: July 16, 2025
Sanofi is a leading French innovator in the pharmaceutical industry and an established name in the European stock market. In this article, you can read all about the Sanofi share: price development, dividend policy, and prospects. Subscribe to our newsletter here and always stay informed.
- Year of incorporation: 1973
- Year added to the EUROSTOXX 50: 1998
- Highest share price ever: €111.40 in March 2025
- Average trading volume: Approx. 1.81 million shares per day
- Share price performance over the past 12 months: -9,13%
Introduction about the company
Sanofi is a global player in innovative medicines, vaccines and healthcare products. Headquartered in Paris, the company focuses on indications such as immunology, oncology, rare diseases and vaccines through Sanofi Pasteur. With a strong focus on R&D, patented medicines and a strategic divestment of the consumer division, Sanofi remains one of the leading pharma groups in Europe.
Key figures & performance
In 2024, Sanofi achieved sales of €43.77 billion, up from the previous year, and net profit reached €8.02 billion, underscoring its robust financial base and strong profitability. As of mid-July 2025, the market capitalization was approximately €102.22 billion. Sanofi has approximately 86,000 employees worldwide.
History & development
Sanofi was founded in 1973 and grew through mergers with Synthélabo (1999) and Aventis (2004). In 2021-2024, the company expanded its portfolio with biotech acquisitions such as Genzyme, Translate Bio and Kadmon. In early 2025, Sanofi announced the carve-out of its Consumer Healthcare business through the sale of Opella, while retaining a minority stake. In addition, the company acquired Vigil Neuroscience to strengthen its neurology pipeline.
Sector & competition
Sanofi positions itself in a segment with strong competitors such as Novartis, Roche and Pfizer. While the sector is under pressure from price regulation and patent expiration, biotech alliances, vaccines and rare diseases remain catalysts for growth. Sanofi stands out for its solid R&D pipeline, economies of scale in vaccines and strategic biotech acquisitions.
Sanofi's influence on the EURO STOXX 50
Sanofi has been an important representative of the healthcare sector since the start of the EURO STOXX 50 in 1998. By mid-2025, the stock has a weight of 3.07% in the index. Curious about the complete composition of the EURO STOXX 50? Read all about it here. The stock price is influenced by clinical trial results, patent news, alliances and price regulation trends. The strong fundamental base and strategic divestitures strengthen Sanofi's relevance within the structure of the index.
Investment analysis & outlook
Over the past five years, Sanofi shares fell 6.10%, while the EURO STOXX 50 achieved a 58.38% increase over the same period. This leaves Sanofi clearly behind the broader market. Over the past year, the share price fell further by 9.13%, which seems to be mainly due to sector-wide pressure, uncertainty around product launches and macroeconomic challenges.
Still, there are opportunities for an upward recovery. The sale of the OTC division through the Opella transaction raised about €10 billion, giving room for reinvestment in core businesses and possibly share buybacks. In addition, Sanofi strengthened its pipeline with strategic biotech acquisitions, including Vigil Neuroscience and Inhibrx, and is planning the launch of promising drugs in immunology, vaccines and rare diseases.
Important factors to keep an eye on are clinical trial results, product approvals and developments around drug price regulation in key markets. In summary, despite its underperformance, with a strong balance sheet, reliable dividend policy and a robust pipeline strengthening strategy, Sanofi shows potential for investors with a medium to long horizon.
.webp?width=1096&height=650&name=Sanofi%20koers%20(1).webp)
News & updates
In early 2025, Sanofi completed the sale of 50% of its consumer division Opella, raising about €10 billion and strengthening the company's focus on its core business. Shortly thereafter, a €1.5 billion bond was issued in two tranches in June to support operations and strategic investments. In May, Sanofi announced that it was acquiring Vigil Neuroscience for approximately €435 million, significantly strengthening its neurology pipeline. In addition, a global employee share plan was launched in June, whereby employees receive shares at a discount and free matching, encouraging engagement and long-term bonding.
For more information about Sanofi, please visit: www.sanofi.com
Disclaimer: Investing involves risk. Our analysts are not financial advisors. Always consult an advisor when making financial decisions. The information and tips provided on this website are based on our analysts' own insights and experiences. They are therefore for educational purposes only.
.webp)
.webp)
.webp)
